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Objectives: Using synchronized cultures of Plasmodium falciparum, the time- and concentration-
dependent growth changes of erythrocytic parasite stages to DB75, piperaquine, OZ277 and OZ401
were investigated in vitro over a concentration range of 1–1003 the IC50 of piperaquine, OZ277 and
OZ401 and 10–10003 the IC50 of DB75.
Methods: The effects of timed in vitro exposure (1, 6, 12 or 24 h) were monitored by the incorporation
of [3H]hypoxanthine into the parasite nucleic acids.
Results: After 1 h of exposure to the highest concentration of the compound followed by removal of
the compound, the growth of all stages of P. falciparum was reduced to <34% for DB75 and 15% for
piperaquine, OZ277 and OZ401 compared with untreated control parasites. At this time point, no stage-
specific effects were observed at any of the concentrations. Strong inhibition (10% growth) of all
parasite stages was observed when the parasites were exposed to 103 or 1003 the IC50 of OZ277 and
OZ401 for 6 h. At the 6 h incubation time point, DB75 was more active against mature parasite
stages, with the IC50s of young ring forms elevated up to 7-fold. This trend was observed up to 12 h,
but was only statistically significant at the lowest concentration. Interestingly, the stage-specific effect
of DB75 on ring forms was not detectable when washing procedures were omitted. This indicates a
cytostatic action of DB75 on P. falciparum ring forms.
Conclusions: The current study suggests that P. falciparum ring stages are less susceptible to DB75.
A milder and often statistically insignificant stage-specific trend was observed for piperaquine,
whereas OZ277 and OZ401 were equally active against the erythrocytic parasite stages.
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Introduction
The spread of resistance of the mosquito vector to currently
available insecticides, the growing resistance of the parasites to
treatment and the limited success of potential antimalarial vac-
cines have led to the urgent need to optimize existing drugs and
to find new chemotherapeutic agents for the treatment of
malaria, especially agents against Plasmodium falciparum.1
The Medicines for Malaria Venture (MMV), founded in 1999
as a not-for-profit Swiss foundation, aims to discover, develop and
deliver, through effective public–private partnerships, new afford-
able antimalarial drugs that cure patients with a 3 day treatment
regimen.2 One former MMV project focused on an entirely new
class of antimalarial compounds, the diamidines (www.MMV.org).
Diamidines, such as DB75, are known to be active in vitro against
chloroquine-sensitive (NF54) and chloroquine-resistant (K1)
strains of P. falciparum as well as against the blood stage forms of
Plasmodium vivax.3 A second project sponsored by MMV is the
‘ozonide’ project, which has the aim of providing fully synthetic
peroxides for patients with uncomplicated P. falciparum
malaria. The pre-clinical candidate OZ277 (RBx11160) was
described by Vennerstrom et al.4 and is currently being developed
by Ranbaxy Laboratories Limited in combination with partner
drugs such as piperaquine (MMV Annual Report 2006; www.
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mmv.org). Other ozonides, such as OZ401 investigated here,
originate out of the ‘OZ next generation’ project.
To our knowledge, the present study describes for the first
time the pharmacodynamic effects of DB75, piperaquine and
OZ401 on P. falciparum cultures by assessing their stage
specificity and rate of action in comparison to those of OZ277,
which was analysed previously.5 A comprehensive knowledge
about their pharmacodynamic properties may help to promote
the development of new antiplasmodial agents and drug combi-
nations, and improve the efficacy of available drugs.
Materials and methods
Parasite cultivation
The drug-sensitive isolate of P. falciparum, NF54, from the
Netherlands and its clone 3D7 were used for the in vitro assays. All
Plasmodium strains were provided by F. Hoffmann-La Roche Ltd
(Basel, Switzerland) and were cultured as described previously.5,6
When required, parasites were synchronized twice with 5%
D-Sorbitol.7 The second treatment was performed 6–8 h after the
first synchronization. This procedure provided a parasite culture
containing 80% young trophozoites (20–24 h old), 75% young
schizonts (36–40 h old) and 90% young ring forms (52–56 h old,
which equals 4–8 h of the next cycle).
Chemicals and materials
DB75 (MW: 377) was obtained from Immtech Pharmaceuticals, Inc.
(Vernon Hills, IL USA), piperaquine tetraphosphate (MW: 928)
from Ranbaxy Laboratories Limited (Gurgaon, India), OZ277 tosy-
late (MW: 565) and OZ401 mesylate (MW: 566) were provided by
J. L. Vennerstrom (University of Nebraska Medical Center, NE,
USA), pyrimethamine (MW: 249) was a gift from F. Hoffmann-
La Roche Ltd (Basel, Switzerland) and [8-3H]hypoxanthine was
purchased from Amersham Bioscience (Buckinghamshire, UK).
Antimalarial compounds were dissolved in DMSO at 10 mg/mL.
The stock solutions were kept at 48C for not more than 6 months.
Dilutions were prepared from the stock solution immediately before
use. The DMSO concentration in experiments had no inhibitory
effect on parasite cultures.
In vitro growth inhibition assay and washing procedure
P. falciparum growth was assessed by measuring incorporation of
the nucleic acid precursor [3H]hypoxanthine.8 IC50 values for NF54
were found to be 17+ 0.3 ng/mL for DB75,3 8.5+0.1 ng/mL for
piperaquine,9 0.91+0.12 ng/mL for OZ277,4 1.0+0.0 ng/mL for
OZ401 and 5.6+0.5 ng/mL for pyrimethamine.5 Synchronized cul-
tures of young NF54 trophozoites with parasite counts of 0.15% and
a haematocrit of 5% were divided into three 10 cm Petri dishes.
Two dishes were further incubated for 16 or 32 h at 378C for matu-
ration into early schizonts or early ring stages. The third dish with
the early trophozoites was used immediately for a 1, 6, 12 or 24 h
exposure to the following four antimalarial compounds: DB75
(final concentrations 20 000, 10 000, 5000, 2500, 1250, 625 and
313 ng/mL), piperaquine (final concentrations 1000, 500, 250, 125,
63, 31 and 15.6 ng/mL), and OZ277 and OZ401 (final concen-
trations 100, 50, 25, 13, 6, 3 and 1.6 ng/mL). The 1 and 24 h time
points and the 6 and 12 h time points were performed separately. As
a validation of our methodology, the stage-specific effect of 24 h of
pyrimethamine incubation (final concentrations 500, 250, 125, 63,
31, 15.6 and 8 ng/mL) was also investigated over a concentration
range of 1–100 the IC50 of the compound. Similar to earlier
findings,5,10 pyrimethamine was found to be ineffective against ring
and trophozoite stages (data not shown). The only sensitive parasite
blood forms were the schizonts. After the respective incubation
times for the parasite-compound mixture, the plates were washed
four times resulting in a .1000-fold dilution of free compound. After
another incubation period of 24 h at 378C in the atmosphere described
above, the plates were frozen at 2208C or directly processed as
described.5 With DB75, three additional assays were performed,
where after 12 h the compound was not removed by washing. Two
assays were performed with young 3D7 ring forms and one assay
with young NF54 ring forms, giving very similar results.
Results
Assessment of stage-specific drug activity
The in vitro stage-specific effects of 1, 6, 12 or 24 h of compound
exposure were investigated with synchronous cultures of
P. falciparum NF54. Figure 1 shows parasite growth plotted
against incubation time for three selected compound concen-
trations: 10 IC50, 100 IC50 and 1000 IC50 (for
DB75), and 1 IC50, 10 IC50 and 100 IC50 (for pipera-
quine, OZ277 and OZ401). Table 1 demonstrates the comparison
of the IC50 values of DB75, piperaquine, OZ277 and OZ401
evaluated for ring, trophozoite and schizont stages.
After 1 h of exposure at the highest compound concentration
(100 the IC50 for piperaquine, OZ277 and OZ401, and
1000 the IC50 for DB75) followed by the removal of the
compound, the growth of all parasite stages was rapidly reduced
and with no obvious stage specificity (Figure 1). For pipera-
quine, OZ277 and OZ401, the growth decreased to ,15% com-
pared with untreated control parasites. In the case of DB75, the
growth ranged from 16% to 34%.
When the parasites were exposed to OZ277 and OZ401 for
6 h, again all stages were similarly affected. For DB75,
however, the young ring forms were less susceptible than the
mature stages (Figure 1). At the 6 h time point, the P values for
the difference between the ring and trophozoite stages or ring
and schizont stages were 0.0003 and 0.00001 (medium concen-
trations), and 0.02 and 0.02 (low concentrations). At the 12 h
time point, the P values for DB75 were only statistical signifi-
cant at the lowest concentration (0.03 and 0.02), respectively.
After 24 h, we observed no more stage-specific profiles. A
similar, however mostly statistically insignificant stage-specific
trend was found for piperaquine (Figure 1).
Analysis of the IC50 values of the different parasite stages
(Table 1) showed that for DB75 the IC50 values of young ring
stages were up to 7 higher than those of trophozoites and schi-
zonts at the 6 h time point (P ¼ 0.01 for both). A mostly statisti-
cally insignificant stage-specific activity was found for
piperaquine (P ¼ 0.04 and 0.05, respectively). This trend could
be observed up to 12 h, in particular for DB75, but without
being statistically significant for either molecule.
Interestingly, the stage-specific effect of DB75 on ring forms
could no longer be observed when washing procedures were
omitted. Three independent 12 h experiments resulted in an
average IC50 value of 180 ng/mL for young ring forms, which is
9-fold lower than the IC50 value obtained when the parasitized
cells were washed (Table 1, 1638 ng/mL) and which is similar
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to the IC50 values of the trophozoite and schizont stages
(Table 1, 304 and 270 ng/mL).
Discussion
To our knowledge, this is the first report on the pharmaco-
dynamic effects of DB75, piperaquine and OZ401 on
P. falciparum. Understanding the stage specificity and onset of
action of new chemotherapeutic agents for the treatment of
malaria is considered to be of clinical importance, particularly
in view of the increasing development of resistance in parasites
to known antimalarial agents.
In our pharmacodynamic studies, we found that the growth of
all parasite stages was similarly affected after 1 h of exposure to
DB75, piperaquine, OZ277 and OZ401 at all evaluated concen-
trations. However, exposure of piperaquine, and especially DB75,
to malarial parasites for 6 or 12 h showed that they were more
active against the mature parasite stages (up to 7-fold lower
IC50s) than against the young ring forms (Figure 1 and Table 1).
The University of Chapel Hill performed similar
[3H]hypoxanthine incorporation studies with DB75.11 For the
trophozoite parasite stages, the Meshnick IC50 data were very
similar to our 12 h IC50 data [268 ng/mL (711 nM) versus
304 ng/mL], but differed 30 for the ring stages [54 ng/mL
(143 nM) versus 1638 ng/mL]. In order to determine whether
the washing steps omitted by the Chapel Hill group could be the
explanation for the different IC50 values between the two labs,
we performed three independent 12 h experiments without the
removal of DB75. Indeed, removing the washing step resulted in
IC50 values for young ring forms that were very similar between
the two laboratories [54 ng/mL (143 nM) versus 180 ng/mL].
This indicates a cytostatic action of DB75 on P. falciparum ring
forms.
For DB75, it should also be noted that comparable growth
inhibitions relative to the other three compounds could only be
achieved with a 10 higher compound concentration. We con-
clude that DB75 can act as fast as the other three compounds,
but only at a 10 higher concentration.
For OZ277 and OZ401, we found that the growth of all para-
site stages was affected in a similar way at all time points and
concentrations. These observations are mostly in line with what
was reported earlier for OZ277.5 The only difference was found
at the highest concentration at the 1 h time point, where our
earlier findings at the highest OZ277 concentration indicated that
young ring forms were 2-fold less sensitive compared with
mature stages.5 A possible explanation could be that the data in
the previous study were from two independent experiments,
whereas in the present study three independent experiments were
performed. Another factor that possibly could have contributed to
DB75
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Figure 1. Stage-dependent effects of DB75 (10, 100 and 1000 the IC50), piperaquine, OZ277 and OZ401 (1, 10 and 100 the IC50)
on [3H]hypoxanthine incorporation in synchronous cultures of P. falciparum strain NF54. Compounds were added for 1, 6, 12 or 24 h. After removal of the
compounds, parasites were incubated for another 24 h in the presence of [3H]hypoxanthine. Compound effects are expressed as the percentage of growth of
the respective development stage relative to an untreated control. The open bar is the ring stage, the filled bar is the trophozoite stage and the hatched bar
is the schizont stage. Each bar represents the mean+SD of n ¼ 3 independent experiments. Significant differences between ring and trophozoite stages
(*P, 0.05), or ring and schizont stages (*P, 0.05) were determined by Student’s t-tests.
Stage specificity of DB75, piperaquine, OZ277 and OZ401
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the observed data variability is the very short compound incu-
bation time (1 h).
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Table 1. Mean IC50 values for DB75, piperaquine, OZ277 and
OZ401 determined by the [3H]hypoxanthine assay for synchronized




Mean IC50 [mean+SD (ng/mL)]
ring trophozoite schizont
DB75
1 10 587+ 2275 7267+3270 10 352+5446
6 5577+ 1799 942+ 525* 822+433*
12 1638+ 943 304+ 27 270+26
24 346+ 98 285+ 9 263+15
Piperaquine
1 35+8 22+7 18+ 2*
6 55+10 17+11* 25+ 16
12 39+24 21+6 19+ 7
24 13+1.2 16+8 10+ 0.6*
OZ277
1 6.3+ 3.5 6.2+1.4 17+ 11
6 3.7+ 3.0 1.9+0.6 3.4+1.6
12 3.0+ 1.5 2.0+1.0 3.0+2.1
24 1.4+ 0.1 1.3+0.3 1.2+0.2
OZ401
1 1.4+ 0.1 2.1+0.5 6.1+2.9
6 1.9+ 0.6 1.8+0.2 6.3+2.6
12 2.2+ 0.9 2.0+1.0 4.3+2.5
24 1.4+ 0.1 2.0+0.3 1.6+0.3
Cultures were initiated at a parasitaemia of 0.15% and a hematocrit of 5%,
and incubated for 1, 6, 12 and 24 h. After removal of the compounds,
parasites were incubated for another 24 h in the presence of
[3H]hypoxanthine. Data are the means+SD of n ¼ 3 independent
experiments. Significant differences between ring and trophozoite stages, or
ring and schizont stages were determined by Student’s t-tests (*P, 0.05).
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